{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:42:45Z","timestamp":1783539765350,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10620-018-5178-1","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T21:39:42Z","timestamp":1530567582000},"page":"2695-2702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-9613","authenticated-orcid":false,"given":"Talal","family":"Al-Taweel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Strohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"5178_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","volume":"134","author":"M Toruner","year":"2008","unstructured":"Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929\u2013936.","journal-title":"Gastroenterology"},{"key":"5178_CR2","first-page":"1070","volume":"5","author":"FN Aberra","year":"2007","unstructured":"Aberra FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:1070\u20131075.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"5178_CR3","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthr Rheum. 2003;48:2122\u20132127.","journal-title":"Arthr Rheum"},{"key":"5178_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098\u20131104.","journal-title":"N Engl J Med"},{"key":"5178_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","volume":"146","author":"D Menzies","year":"2007","unstructured":"Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340\u2013354.","journal-title":"Ann Intern Med"},{"key":"5178_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","volume":"4","author":"M Pai","year":"2004","unstructured":"Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761\u2013776.","journal-title":"Lancet Infect Dis"},{"key":"5178_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/CMR.00034-13","volume":"27","author":"M Pai","year":"2014","unstructured":"Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3\u201320.","journal-title":"Clin Microbiol Rev"},{"key":"5178_CR8","unstructured":"Centre for Communicable D, Infection C, Association CL, et al. Canadian Tuberculosis Standards (7th Edition): Public Health Agency of Canada, 2014."},{"key":"5178_CR9","first-page":"21","volume":"22","author":"G Andrisani","year":"2013","unstructured":"Andrisani G, Armuzzi A, Papa A, et al. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. J Gastrointestin Liver Dis. 2013;22:21\u201325.","journal-title":"J Gastrointestin Liver Dis"},{"key":"5178_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ibd.21427","volume":"17","author":"P Papay","year":"2011","unstructured":"Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:84\u201390.","journal-title":"Inflamm Bowel Dis"},{"key":"5178_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/ibd.21329","volume":"17","author":"BJ Qumseya","year":"2011","unstructured":"Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77\u201383.","journal-title":"Inflamm Bowel Dis"},{"key":"5178_CR12","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1111\/j.1572-0241.2008.02050.x","volume":"103","author":"AM Schoepfer","year":"2008","unstructured":"Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008;103:2799\u20132806.","journal-title":"Am J Gastroenterol"},{"key":"5178_CR13","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/ibd.22901","volume":"18","author":"N Shahidi","year":"2012","unstructured":"Shahidi N, Fu YT, Qian H, et al. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034\u20132042.","journal-title":"Inflamm Bowel Dis"},{"key":"5178_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn\u2019s Colitis. 2014;8:443\u2013468.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5178_CR15","doi-asserted-by":"crossref","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221\u2013S247.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"5178_CR16","unstructured":"WHO. Global tuberculosis report 2016: World Health Organization, Geneva, 2016."},{"key":"5178_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/ecco-jcc\/jjw110","volume":"10","author":"B Agudo","year":"2016","unstructured":"Agudo B, D\u00edaz G, Gonz\u00e1lez-Lama Y. Adalimumab-receiving ulcerative colitis patient suffered latent tuberculosis reactivation despite correct chemoprophylaxis and was successfully treated while on anti-tumour necrosis factor therapy. J Crohn\u2019s Colitis. 2016;10:1453\u20131454.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5178_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ecco-jcc\/jjx108","volume":"12","author":"MJ Jong de","year":"2018","unstructured":"de Jong MJ, Roosen D, van Tubergen A. The prevalence of latent tuberculosis and hepatitis B after systematic screening of patients prescribed biological therapy in a low-endemic area. J Crohn\u2019s Colitis. 2018;12:124\u2013125.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5178_CR19","first-page":"89","volume":"1","author":"D Nguyen","year":"2001","unstructured":"Nguyen D, Menzies D. Diagnosis and treatment of latent TB infection. Can J CME. 2001;1:89\u201397.","journal-title":"Can J CME"},{"key":"5178_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1378\/chest.07-2193","volume":"133","author":"JC Choi","year":"2008","unstructured":"Choi JC, Shin JW, Kim JY, et al. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest. 2008;133:1415\u20131420.","journal-title":"Chest"},{"key":"5178_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1164\/rccm.200811-1704OC","volume":"180","author":"RN Zyl-Smit van","year":"2009","unstructured":"van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009;180:49\u201358.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5178-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:20:33Z","timestamp":1562095233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5178-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["5178"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5178-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"2 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T Al-Taweel has received travel\/accommodation\/meeting expenses from Abbvie, Janssen, Newbridge and Novartis, lecture fees from Janssen and Abbvie and consulting fees from Abbvie and Takeda. A. Bitton has received research financial support from Abbvie, lecture fees from Abbvie, Janssen and Shire and consulting fees from Abbvie, Janssen, Shire, Ferring and Takeda. W. Afif has received consulting fees from Abbvie, Janssen, Shire, Ferring and Takeda. T. Bessissow has received research financial support from Abbvie, lecture fees from Abbvie, Janssen, Takeda, Shire, Actavis and Ferring and consultancy fees from Abbvie, Janssen, Takeda, Shire and Actavis. The remaining authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"T Al-Taweel MBChB, KMSC, MRCP(UK), MRCPS(Glasg).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor of Article"}}]}}